Mirum Pharmaceuticals (NASDAQ:MIRM) CEO Sells $2,960,400.00 in Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CEO Christopher Peetz sold 30,000 shares of the stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $98.68, for a total value of $2,960,400.00. Following the completion of the transaction, the chief executive officer owned 194,440 shares of the company’s stock, valued at approximately $19,187,339.20. This trade represents a 13.37% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Christopher Peetz also recently made the following trade(s):

• On Monday, August 10th, Christopher Peetz sold 20,000 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $98.92, for a total transaction of $1,978,400.00.
• On Monday, July 6th, Christopher Peetz sold 20,000 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $122.27, for a total transaction of $2,445,400.00.

Mirum Pharmaceuticals Stock Up 0.3%

NASDAQ:MIRM opened at $100.90 on Friday. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.86 and a quick ratio of 2.74. The firm’s 50-day moving average price is $109.09 and its 200-day moving average price is $101.73. The company has a market capitalization of $6.55 billion, a PE ratio of -6.93 and a beta of 0.49. Mirum Pharmaceuticals, Inc. has a 1-year low of $63.23 and a 1-year high of $130.00.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.32). The business had revenue of $176.24 million for the quarter, compared to analysts’ expectations of $166.33 million. Mirum Pharmaceuticals had a negative net margin of 139.18% and a negative return on equity of 36.28%. The company’s revenue was up 37.9% on a year-over-year basis. During the same period last year, the business earned ($0.12) earnings per share. On average, equities analysts predict that Mirum Pharmaceuticals, Inc. will post -1.31 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently commented on MIRM. UBS Group set a $137.00 target price on Mirum Pharmaceuticals in a research note on Thursday, August 27th. Wall Street Zen downgraded shares of Mirum Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Sunday. Morgan Stanley set a $137.00 price objective on shares of Mirum Pharmaceuticals in a report on Thursday, August 6th. CLSA set a $146.00 price objective on Mirum Pharmaceuticals in a research report on Monday, June 15th. Finally, Royal Bank Of Canada cut their target price on Mirum Pharmaceuticals from $148.00 to $135.00 and set an “outperform” rating on the stock in a research note on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Mirum Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $137.31.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in MIRM. Nan Fung Trinity HK Ltd. raised its stake in Mirum Pharmaceuticals by 45.6% during the 4th quarter. Nan Fung Trinity HK Ltd. now owns 227,479 shares of the company’s stock valued at $17,969,000 after buying an additional 71,214 shares during the last quarter. Emerald Advisers LLC boosted its stake in shares of Mirum Pharmaceuticals by 8.2% in the 1st quarter. Emerald Advisers LLC now owns 397,263 shares of the company’s stock worth $36,699,000 after buying an additional 30,129 shares during the last quarter. BlackRock Inc. bought a new stake in shares of Mirum Pharmaceuticals in the second quarter worth $513,945,000. SBI Okasan Asset Management Co.Ltd. bought a new stake in shares of Mirum Pharmaceuticals in the fourth quarter worth $1,283,000. Finally, Rice Hall James & Associates LLC purchased a new stake in Mirum Pharmaceuticals during the second quarter valued at $12,956,000.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.